MYND Life Sciences Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jul '24 Jul 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019
Cost of Revenue	0.33	0.33	0.23	-	-	-
Gross Profit	-0.33	-0.33	-0.23	-	-	-
Selling, General & Admin	0.6	1.17	1.49	1.96	0.06	0
Research & Development	0.33	0.28	1.18	1.08	-	-
Operating Expenses	0.95	1.5	2.84	4.29	0.06	0
Operating Income	-1.29	-1.83	-3.06	-4.29	-0.06	-0
Interest Expense	-0.24	-0.73	-0.66	-0.13	-	-
Other Non Operating Income (Expenses)	-0	0.04	0.01	-	-	-
EBT Excluding Unusual Items	-1.52	-2.52	-3.71	-4.43	-0.06	-0
Gain (Loss) on Sale of Assets	1	1	-	-	-	-
Asset Writedown	-	-	-	-0.11	-	-
Other Unusual Items	-0.02	-	0.01	-	-	-
Pretax Income	-0.54	-1.52	-3.7	-4.54	-0.06	-0
Income Tax Expense	-	-	-0.13	-0.17	-	-
Net Income	-0.54	-1.52	-3.57	-4.37	-0.06	-0
Net Income to Common	-0.54	-1.52	-3.57	-4.37	-0.06	-0
Shares Outstanding (Basic)	47	47	47	45	28	2
Shares Outstanding (Diluted)	47	47	47	45	28	2
Shares Change (YoY)	-0.92%	1.27%	3.83%	59.27%	1554.82%	-
EPS (Basic)	-0.01	-0.03	-0.08	-0.10	-0.00	-0.00
EPS (Diluted)	-0.01	-0.03	-0.08	-0.10	-0.00	-0.00
Free Cash Flow	-0.17	-0.2	-1.82	-3.03	-0	-0
Free Cash Flow Per Share	-0.00	-0.00	-0.04	-0.07	-	-
EBITDA	-1.28	-1.83	-3.06	-4.28	-	-
D&A For EBITDA	0	0	0	0.01	-	-
EBIT	-1.29	-1.83	-3.06	-4.29	-0.06	-0
Advertising Expenses	-	0.36	0.14	0.41	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.